BIOGEN AVONEX SALES, ORPHAN PROTECTION CREATE JULY SIZZLE; STOCK UP 6-1/4
Executive Summary
Biogen rebounded in July after two months of decline as the launch of Avonex for multiple sclerosis and the drug's orphan exclusivity keeping a second competitor from Berlex off the market helped Biogen sizzle